The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population

被引:27
作者
Chen, B [1 ]
Zhang, WX [1 ]
Cai, WM [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pharm, Shanghai 200025, Peoples R China
关键词
Chinese; genotype; N-acetyltransferase2 (NAT2); phenotype; polymorphism;
D O I
10.1007/s00228-006-0110-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To determine the phenotype and genotype of NAT2 in a Chinese population and study the influence of various NAT2 genotypes on the NAT2 activity. Methods: A reverse dot blot method was used to detect the genotype of NAT2 in 120 healthy Chinese subjects. All subjects were given a single dose of 500 mg sulphadimidine (SM2). The plasma concentration of SM2 and acetyl-SM2 (AcSM2) 6 h after administration was determined. Molar metabolic ratio (MR) was calculated by the ratio of AcSM2 to AcSM2+SM2. Results: Totals of 53 (44.2%), 47 (39.2%) and 20 (16.7%) subjects were homozygotes for wild type (wt/wt), heterozygotes for mutant (m/wt) and homozygotes for mutant (m/m), respectively. The MR of 120 subjects was 0.714 +/- 0.237. Twenty subjects (16.7%) were classified as poor metabolizers. All subjects in the m/m group were poor metabolizers. The MRs of the wt/wt, m/wt and m/m groups were 0.886 +/- 0.060, 0.719 +/- 0.089 and 0.246 +/- 0.105 (P < 0.001), respectively. There was a significant difference between different NAT2 m/wt genotypes (P < 0.001) and m/m genotypes (P < 0.001). MR correlated well with NAT2 genotypes (r=0.947). Conclusion: Various NAT2 genotypes have a significant impact on the metabolic activity of NAT2 in Chinese people.
引用
收藏
页码:355 / 359
页数:5
相关论文
共 20 条
[1]  
Agundez JAG, 1996, PHARMACOGENETICS, V6, P423
[2]  
[陈冰 Chen Bing], 2004, [中国药理学通报, Chinese Pharmacological Bulletin], V20, P1269
[3]  
DEGUCHI T, 1990, J BIOL CHEM, V265, P12757
[4]  
EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157
[5]  
Gross M, 1999, CANCER EPIDEM BIOMAR, V8, P683
[6]  
HEIN DW, 1995, CANCER RES, V55, P3531
[7]   PERIPHERAL VASCULAR EFFECTS OF BETA-BLOCKERS [J].
HEINTZEN, MP ;
STRAUER, BE .
EUROPEAN HEART JOURNAL, 1994, 15 :2-7
[8]  
Hiratsuka Masahiro, 2002, Drug Metab Pharmacokinet, V17, P357, DOI 10.2133/dmpk.17.357
[9]   Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? [J].
Kinzig-Schippers, M ;
Tomalik-Scharte, D ;
Jetter, A ;
Scheidel, B ;
Jakob, V ;
Rodamer, M ;
Cascorbi, I ;
Doroshyenko, O ;
Sörgel, F ;
Fuhr, U .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) :1733-1738
[10]  
LIN HJ, 1993, AM J HUM GENET, V52, P827